// Company Overview //
| Stock Name | 健世科技－Ｂ |
|---|---|
| Stock Code | 09877 |
| Company Full Name | 健世科技－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事開發用於治療結構性心臟病的介入產品。 |
| Listing Date | 2022-10-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省寧波市杭州灣新區濱海四路777號B區5號樓 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | https://www.jenscare.com/investor |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2022-09-23 |
| Offer Price | HK$ 27.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1 shares |
| Entry Threshold | HK$ 28 |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | — (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | —x |
| Valid Applications | 2,160 |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 22,462,400 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | -18.93 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 69,800,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 28.0 |
| First Day Change | 1.62% |
| First Day Volume | 1466000.0 |
| First Day Turnover | 41947900.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約65.0%或約100.6百萬港元將分配予我們核心產品（即LuX-Valve及KenValve）的研發、制造及商業化； 2、約25.0%或約38.7百萬港元將分配予產品管線的其他在研產品（包括LuXValve Plus、KenFlex及二尖瓣產品）的研發、臨床試驗及產品注冊； 3、約10.0%或約15.5百萬港元將用于營運資金及一般企業用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
中国国际金融香港证券有限公司
花旗环球金融亚洲有限公司
整体协调人 (4)
中国国际金融香港证券有限公司
花旗环球金融亚洲有限公司
华泰金融控股（香港）有限公司
农银国际证券有限公司
联席账簿管理人 (7)
中国国际金融香港证券有限公司
花旗环球金融亚洲有限公司
华泰金融控股（香港）有限公司
农银国际证券有限公司
交银国际证券有限公司
富途证券国际（香港）有限公司
老虎证券（香港）环球有限公司
联席牵头经办人 (8)
中国国际金融香港证券有限公司
花旗环球金融亚洲有限公司
华泰金融控股（香港）有限公司
农银国际证券有限公司
交银国际证券有限公司
富途证券国际（香港）有限公司
老虎证券（香港）环球有限公司
元库证券有限公司
// Cornerstone Investors //
Allotment Results Announcement
| # | Investor Name | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|
| 1 | 先健科技公司（「先健」） 20.0 | 5,646,600 | 69.91% | 1.35% | — | — |
// Directors & Management //
| Chairman | 呂世文 |
|---|---|
| Company Secretary | 李遠源 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 呂世文及關連人士(36.03%);李輝及關連人士(14.49%);潘斐及關連人士(7.85%);高瓴資本管理有限公司(5.21%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 1 | 1 | 1 | 1.00 |
| 200 | 1,024 | 594 | 116.02 |
| 400 | 78 | 12 | 230.76 |
| 600 | 38 | 27 | 342.12 |
| 800 | 14 | 3 | 442.88 |
| 1,000 | 41 | 28 | 536.60 |
| 1,200 | 8 | 8 | 600.00 |
| 1,294 | 864 | 864 | 543.48 |
| 1,400 | 8 | 4 | 700.00 |
| 1,600 | 10 | 9 | 780.00 |
| 1,800 | 6 | 2 | 866.70 |
| 2,000 | 29 | 20 | 938.00 |
| 3,000 | 11 | 11 | 1400.10 |
| 4,000 | 7 | 7 | 1800.00 |
| 5,000 | 2 | 2 | 2200.00 |
| 6,000 | 2 | 2 | 2599.80 |
| 7,000 | 7 | 7 | 3000.20 |
| 8,000 | 1 | 1 | 3400.00 |
| 10,000 | 6 | 6 | 4200.00 |
| 50,000 | 1 | 1 | 21000.00 |
| 160,000 | 1 | 1 | 67200.00 |
Pool B (Large Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 404,000 | 1 | 1 | 404000.00 |
Allotment Benchmarks
